FAKTOR-OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 11:35:37 2024-06-05 EDT | ||
| 2.52 EUR | -8.70% |
|
| Current month | -3.50% | ||
| 1 month | -35.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 2.52 | -8.70% |
| 24-06-04 | 2.76 | +4.55% |
| 24-06-03 | 2.64 | -7.69% |
| 24-05-31 | 2.86 | +12.60% |
| 24-05-30 | 2.54 | -5.58% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 11:35 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ4H3L |
| ISIN | DE000SQ4H3L2 |
| Date issued | 2022-11-18 |
| Strike | 185.7 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 6.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.64 € |
|---|---|
| Lowest since issue | 2.11 € |
| Spread | 0.01 € |
| Spread % | 0.39% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.3
USD
Average target price
142.8
USD
Spread / Average Target
-1.74%
- Stock Market
- Certificates
- Certificat
